Piper Sandler analyst Adam Maeder lowered the firm’s price target on Nevro to $37 from $38 and keeps an Underweight rating on the shares. The analyst updated models in medical technology and devices to reflect recent company updates.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO: